Samsung Epis Holdings activates China R&D center
Samsung Epis Holdings has officially opened its China R&D center, a strategic move aimed at bolstering its novel drug development capabilities. With this launch, cooperation with the Chinese biotechnology ecosystem is expected to gain full momentum, particularly in the field of antibody-drug conjugates (ADCs), an area of intense focus for its subsidiary..